Effect of Rebamipide for NSAID-Induced Small-intestinal Injuries
NSAIDs-induced Small-intestinal Injuries
Enrolment: 60 · Results not recorded
Loading the evidence…
Drug
1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
NSAIDs-induced Small-intestinal Injuries
Enrolment: 60 · Results not recorded
Gastroesophageal Reflux
Enrolment: 143 · Results not recorded
Dry Eye Syndromes
Enrolment: 188 · Results not recorded
Rheumatoid Arthritis
Enrolment: 39 · Results not recorded
Gastric Ulcer Induced by Anti-platelet Agent · Duodenal Ulcer Induced by Anti-platelet Agent
Enrolment: 142 · Results not recorded
Dry Eye Syndromes · Keratoconjunctivitis Sicca
Enrolment: 220 · Results not recorded
Dry Eye Syndromes
Enrolment: 290 · Results not recorded
Colitis, Ulcerative
Enrolment: 124 · Results not recorded
Acute Gastritis · Chronic Gastritis
Enrolment: 600 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Radiation-induced colitis: 13 Gy abdominal irradiation
Rebamipide alleviated acute radiation-induced colitis, increased goblet cell numbers and mucin 2 expression, inhibited inflammation and protected against bacterial translocation
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.
Model: Acute colitis with colonic ulceration induced by intrarectal trinitrobenzene sulfonic acid; complemented by in vitro wound healing (scratch) assays in rat intestinal epithelial cells
Intracolonic rebamipide accelerated healing of trinitrobenzene sulfonic acid induced ulcers and significantly inhibited the rise in colonic wet weight. In vitro it enhanced epithelial cell migration through extracellular signal-regulated kinase phosphorylation and Rho kinase activation.
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.